All tracked trials

Phase 2 and Phase 3 cancer trials run by companies on the Nasdaq or New York Stock Exchange.

1,669 trials · most recently edited first

PBYIPuma Biotechnology, Inc.
0Calm
A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)
Signing up patientsPhase 250 patientsMain results: Mar 31, 2028
RCUSArcus Biosciences, Inc.
0Calm
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
Signing up patientsPhase 3720 patientsMain results: Apr 2028
AMGNAmgen
2Calm
Study of Blinatumomab Administration in Chinese Pediatric Participants With Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
Running, no new patientsPhase 218 patientsMain results: Jan 6, 2026
BMYCelgene
10Calm
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
Signing up patientsPhase 2/31,541 patientsMain results: May 29, 2043
GMABGenmab
0Calm
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
Signing up patientsPhase 1/2560 patientsMain results: May 2028
ADAGAdagene Inc
0Calm
ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors
Signing up patientsPhase 1/2186 patientsMain results: Jun 30, 2027
AVBPArriVent BioPharma, Inc.
0Calm
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Signing up patientsPhase 3480 patientsMain results: Feb 2029
TYRATyra Biosciences, Inc
0Calm
Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial Carcinoma
Signing up patientsPhase 2285 patientsMain results: Oct 2030
AZNAstraZeneca
0Calm
Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib
Running, no new patientsPhase 2367 patientsMain results: Aug 23, 2024
MRKMerck Sharp & Dohme LLC
5Calm
A Clinical Trial of Gocatamig (MK-6070) With Durvalumab in Participants With Small Cell Lung Cancer (MK-6070-004)
Not started yetPhase 3564 patientsMain results: Dec 8, 2031
TAKTakeda
5Calm
A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer
Signing up patientsPhase 31,200 patientsMain results: Nov 1, 2028
GMABGenmab
0Calm
A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)
Running, no new patientsPhase 3621 patientsMain results: Feb 2028
MRKMerck Sharp & Dohme LLC
5Calm
MK-2870-U01 Substudy 1: A Clinical Trial of Sacituzumab Tirumotecan to Treat Prostate Cancer (MK-2870-01A)
Not started yetPhase 1/2290 patientsMain results: Jun 29, 2032
RCUSArcus Biosciences, Inc.
0Calm
Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Running, no new patientsPhase 3610 patientsMain results: Nov 30, 2030
VSTMVerastem, Inc.
12Calm
A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
Signing up patientsPhase 3270 patientsMain results: Oct 15, 2028
GSKGlaxoSmithKline
0Calm
A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial Cancer
Running, no new patientsPhase 241 patientsMain results: Dec 14, 2026
AZNAstraZeneca
0Calm
A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS
Running, no new patientsPhase 2103 patientsMain results: Oct 27, 2026
BNTXBioNTech SE
0Calm
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)
Signing up patientsPhase 2/31,580 patientsMain results: Jan 2029
AVBPArriVent BioPharma, Inc.
0Calm
Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)
Running, no new patientsPhase 3398 patientsMain results: Oct 6, 2026
AZNAstraZeneca
0Calm
A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Signing up patientsPhase 1/2164 patientsMain results: Jul 4, 2028
AZNAstraZeneca
0Calm
A Study to Evaluate Surovatamig Combined With R-CHOP in Participants of 18 to < 80 Years of Age With Previously Untreated Large B-cell Lymphoma With IPI Score 2 to 5
Not started yetPhase 31,200 patientsMain results: Sep 2, 2030
AZNAstraZeneca
0Calm
A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors
Running, no new patientsPhase 2477 patientsMain results: Mar 23, 2027
IRONDisc Medicine, Inc
0Calm
A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)
Running, no new patientsPhase 260 patientsMain results: Jul 2027
MRKMerck Sharp & Dohme LLC
5Calm
MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)
Signing up patientsPhase 3400 patientsMain results: Oct 26, 2039
MRKMerck Sharp & Dohme LLC
5Calm
A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)
Signing up patientsPhase 2150 patientsMain results: Apr 9, 2032